The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017 - PubMed (original) (raw)
The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017
Mimi Zhai et al. Sci Rep. 2021.
Abstract
Nonalcoholic steatohepatitis (NASH) has rapidly become the most common cause of chronic liver diseases. We aimed to explore the incidence and distribution characteristics of NASH by sex, region and sociodemographic index (SDI). We collected data, including sex and region, on NASH-related liver cirrhosis from the 2017 GBD study. The age-standardized incidence rates (ASRs) and estimated annual percentage changes (EAPCs) were used to estimate the incidence trend and distribution characteristics. Globally, the incidence of liver cirrhosis caused by NASH increased from 178,430 cases in 1990 to 367,780 cases in 2017, an increase of approximately 105.56%. The ASR of NASH increased by an average of 1.35% per year (95% CI 1.28-1.42). Meanwhile, large differences in the ASR and the EAPC were observed across regions. The middle-high SDI region had the highest increase among all five SDI regions, followed by middle SDI region. In addition, Eastern Europe, Andean Latin America and Central Asia showed a more significant growth trend of ASR. In contrast, the high SDI region demonstrated the slowest increasing trend of ASR, and the high-income Asia Pacific demonstrated a decreasing trend among the 21 regions. Liver cirrhosis has caused a huge and rising health burden in many countries and regions. In addition, with the growth of obesity, population and aging, NASH might replace viral hepatitis as the most important cause of liver cirrhosis in the near future. Therefore, appropriate interventions are needed in coming decades to realize early diagnosis and prevention of NASH-related liver cirrhosis.
Conflict of interest statement
The authors declare no competing interests.
Figures
Figure 1
The overall incident cases of liver cirrhosis caused by NASH in 195 countries and territories. (A) The incident cases in 1990 across the world. (B) The incident cases in 2017 across the world. (C) The change in incident cases of liver cirrhosis caused by NASH from 1990 to 2017 across the world. Figures were created by STATA/MP 13.1 software. The SHP data of the world map were converted to STATA data via the “shp2dta” command, and maps were drawn via the “spmap” command after incorporating variables.
Figure 2
The global burden of liver cirrhosis incidence caused by NASH in 195 countries and territories. (A) The ASR of liver cirrhosis incidence caused by NASH in 1990. (B) The ASR of liver cirrhosis incidence caused by NASH in 2017. (C) The ASR trend of liver cirrhosis caused by NASH from 1990 to 2017 across the world. Figures were created via the method mentioned in Fig. 1.
Figure 3
Liver cirrhosis incident cases caused by NASH and SDI regions from 1990 to 2017. Figures were created by STATA/MP 13.1 software. The bar charts were drawn via the “graph bar” command, and the cumulative bar charts were drawn by adding the option “stack”.
Similar articles
- The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
GBD 2017 Cirrhosis Collaborators. GBD 2017 Cirrhosis Collaborators. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-266. doi: 10.1016/S2468-1253(19)30349-8. Epub 2020 Jan 22. Lancet Gastroenterol Hepatol. 2020. PMID: 31981519 Free PMC article. - The burden of liver cirrhosis and underlying etiologies: results from the global burden of disease study 2017.
Zhai M, Long J, Liu S, Liu C, Li L, Yang L, Li Y, Shu B. Zhai M, et al. Aging (Albany NY). 2021 Jan 12;13(1):279-300. doi: 10.18632/aging.104127. Epub 2021 Jan 12. Aging (Albany NY). 2021. PMID: 33436531 Free PMC article. - The burden of liver cirrhosis in mortality: Results from the global burden of disease study.
Ye F, Zhai M, Long J, Gong Y, Ren C, Zhang D, Lin X, Liu S. Ye F, et al. Front Public Health. 2022 Aug 11;10:909455. doi: 10.3389/fpubh.2022.909455. eCollection 2022. Front Public Health. 2022. PMID: 36033800 Free PMC article. - Global burden of myocarditis in youth and middle age (1990-2019): A systematic analysis of the disease burden and thirty-year forecast.
Zhang Y, Feng L, Zhu Z, He Y, Li X. Zhang Y, et al. Curr Probl Cardiol. 2024 Sep;49(9):102735. doi: 10.1016/j.cpcardiol.2024.102735. Epub 2024 Jun 29. Curr Probl Cardiol. 2024. PMID: 38950720 Review. - Nonalcoholic Steatohepatitis: A Review.
Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Sheka AC, et al. JAMA. 2020 Mar 24;323(12):1175-1183. doi: 10.1001/jama.2020.2298. JAMA. 2020. PMID: 32207804 Review.
Cited by
- Use of Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis.
Harrison SA. Harrison SA. Gastroenterol Hepatol (N Y). 2024 Aug;20(6):355-359. Gastroenterol Hepatol (N Y). 2024. PMID: 39193263 Free PMC article. No abstract available. - Trends in the burden of hospitalised patients with cirrhosis in Switzerland: a cross-sectional study of cirrhosis-related hospitalisations between 1998 and 2020.
Favre-Bulle T, Moradpour D, Marques-Vidal P, Vaucher J. Favre-Bulle T, et al. BMJ Open. 2024 Aug 24;14(8):e081822. doi: 10.1136/bmjopen-2023-081822. BMJ Open. 2024. PMID: 39181561 Free PMC article. - Worldwide burden of liver cancer across childhood and adolescence, 2000-2021: a systematic analysis of the Global Burden of Disease Study 2021.
Wu Z, Xia F, Wang W, Zhang K, Fan M, Lin R. Wu Z, et al. EClinicalMedicine. 2024 Jul 26;75:102765. doi: 10.1016/j.eclinm.2024.102765. eCollection 2024 Sep. EClinicalMedicine. 2024. PMID: 39170941 Free PMC article. - AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases.
Iyer JS, Juyal D, Le Q, Shanis Z, Pokkalla H, Pouryahya M, Pedawi A, Stanford-Moore SA, Biddle-Snead C, Carrasco-Zevallos O, Lin M, Egger R, Hoffman S, Elliott H, Leidal K, Myers RP, Chung C, Billin AN, Watkins TR, Patterson SD, Resnick M, Wack K, Glickman J, Burt AD, Loomba R, Sanyal AJ, Glass B, Montalto MC, Taylor-Weiner A, Wapinski I, Beck AH. Iyer JS, et al. Nat Med. 2024 Oct;30(10):2914-2923. doi: 10.1038/s41591-024-03172-7. Epub 2024 Aug 7. Nat Med. 2024. PMID: 39112795 Free PMC article. - Burden of non-alcoholic fatty liver disease-related cirrhosis and other chronic liver diseases from 1990 to 2019 in China and disease burden trend prediction to 2030.
Peng J, Huang S, Wang P, Luo R, Zhang W, Shi X, Shi L, Zhong X, Lü M, Peng Y, Tang X. Peng J, et al. Chin Med J (Engl). 2024 Jul 19;137(18):2251-3. doi: 10.1097/CM9.0000000000003211. Online ahead of print. Chin Med J (Engl). 2024. PMID: 39030075 Free PMC article. No abstract available.
References
- Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–1858. doi: 10.1016/S0140-6736(18)32279-7. - DOI - PMC - PubMed
- Global Burden of Disease Cancer Collaboration et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol. 2019;12:1749–1768. doi: 10.1001/jamaoncol.2019.2996. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical